An observational study in Epstein-Barr Virus (EBV) and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 2 sites in Australia. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Epstein-Barr Virus Infections with a site in Australia — 3 open to participants now, 5 under way, 2 of them phase 3. Epstein-Barr Virus Infections · Australia.
Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, this one is one of 3 that started in 2026, is the only observational one, and was the 9th registered.
175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.
Browse Epstein-Barr Virus Infections studies →3 of the 10 studies in Epstein-Barr Virus Infections with a site in Australia are open now. Recruiting first, the newest first:
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company · Sites in Australia
Ages 18–25 · Healthy volunteers
ModernaTX, Inc. · Sites in Australia
Ages 18–30 · Healthy volunteers
Pierre Fabre Medicament · Sites in Australia, United States, Austria and 6 more countries
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 29 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 160 across 53 observational studies indexed under Epstein-Barr Virus Infections.
Median enrollment 115 across the 9 interventional studies, 100 across the 1 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 1 study filed under Epstein-Barr Virus Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Epstein-Barr Virus Infections with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07536048Sanofi Pasteur, a Sanofi CompanyA Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years | 2027-05-14 |
| NCT07478952ModernaTX, Inc.A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.
This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period.
Participants will not receive any study intervention (eg, study treatments, vaccines).
Approximately 100 EBV seropositive participants aged 18 to 29 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Procedure: Investigational Procedure
It consists of prospective blood and saliva collections. Study without any IMP administration.
Number of participants with EBV DNA in blood and saliva at each study visit
Time frame: 6 or 12 months
Serology testing indicative of EBV reactivation, measured by anti-VCA IgG/IgM, anti-EBNA-1 IgG and anti-EA IgG at each study visit
Time frame: 6 or 12 months
Levels of IgG antibodies binding to EBV antigens, measured at selected time points in a subset of participants
Time frame: 6 or 12 months
Levels of EBV nAbs in serum measured at selected timepoints in a subset of participants
Time frame: 6 or 12 months
Immunogenicity assessments at baseline to identify antibody signatures that may correlate with the occurrence of EBV reactivations during study period. Neutralizing and IgG binding assays will be performed in a subset of participants
Time frame: 6 or 12 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epstein-Barr Virus Infections →
Sanofi Pasteur, a Sanofi Company →